Agreement with Alexion is JCR’s first international deal for its blood-brain barrier drug delivery technology. Sartoris buys PolyPlus from private equity investors.

In many ways, Mebiopharm's investment experience is illustrative of the challenges facing the bioventure sector as a whole in Japan, or indeed anywhere else. The need to secure sufficient funding and maintain momentum for lead pipeline projects will no doubt sound familiar to the management of any startup looking to commercialize new technology.

A quick-acting, inhaled antipsychotic, Adasuve has been approved in the U.S. and EU, where it will be commercialized by Spain’s Grupo Ferrer. Teva takes over after previous U.S. partner Biovail stepped away upon being bought out by Valeant.

Whether or not the Affordable Care Act survives a Supreme Court review, private equity investors see abundant opportunities in the rapidly reforming U.S. healthcare landscape, although buyers’ and sellers’ different views of the future lead to pricing disparities.